General MedicationsORALGeneric
LYNPARZA
OLAPARIB
Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview LYNPARZA is listed in Drugs@FDA under application 206162 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient OLAPARIB Form and strength CAPSULE;ORAL - 50MG Sponsor ASTRAZENECA Submission history Latest submission status date: 2018-09-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview LYNPARZA is listed in Drugs@FDA under application 206162 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient OLAPARIB Form and strength CAPSULE;ORAL - 50MG Sponsor ASTRAZENECA Submission history Latest submission status date: 2018-09-27 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.